Erlangen, GermanyMay 7, 2026 /PRNewswire/ — Siemens Healthineers today released its financial results for the second quarter of fiscal year 2026, which ended March 31, 2026.
Second Quarter of Fiscal Year 2026
- Equipment book-to-bill ratio of 1.02
- Comparable revenue growth of 6.1% in Imaging, with adjusted EBIT margin of 22.4%
- Comparable revenue growth of 4.7% in Varian, with adjusted EBIT margin of 13.3%
- Comparable revenue decline of 6.5% in Diagnostics, primarily due to structural changes in the Chinese market, with adjusted EBIT margin of 0.9%
- Overall comparable revenue growth of 3.1%
- Adjusted EBIT margin of 14.7%, impacted by tariffs and currency effects
- Adjusted basic earnings per share of €0.53, roughly flat compared to the same period last year
- Free cash flow of €389 million
Outlook for Fiscal Year 2026
Due to structural changes in the Chinese in-vitro diagnostics market and more pronounced inflation expectations this quarter, we have updated our outlook for fiscal year 2026.
We now expect comparable revenue growth of 4.5% to 5.0% for fiscal year 2026 compared to fiscal year 2025 (previously 5% to 6%). Adjusted basic earnings per share are expected to be between €2.20 and €2.30 (previously €2.20 to €2.40).
Bernd Montag, CEO of Siemens Healthineers, stated: “Despite a persistently challenging external environment, our core Imaging and Varian businesses are progressing well together with strong momentum. At the same time, we are initiating next steps to position the company for future growth, creating more options for the Diagnostics business and advancing the optimization of our management team.”
About Siemens Healthineers
Pioneering breakthroughs in healthcare. For everyone. Everywhere. Siemens Healthineers is a leading medical technology company, providing medical devices, solutions, and services, operating in over 180 countries and directly in more than 70 countries. Siemens Healthineers consists of Siemens Healthineers AG (Frankfurt Stock Exchange: SHL) and its subsidiaries. The company is committed to improving access to high-quality healthcare while combating life-threatening diseases. Siemens Healthineers’ business covers medical imaging, in-vitro diagnostics, cancer care, and minimally invasive therapies, and it strengthens each of its businesses through digital technologies and artificial intelligence. As of the end of fiscal year 2025 (September 30, 2025), Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion.
For more information, please visit the Siemens Healthineers official website: www.siemens-healthineers.com